

PMV Pharmaceuticals, Inc. (PMVP)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001699382

PMV Pharmaceuticals, Inc.		
PMVP; healthcare		
Grade	None 6 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025	
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$12.5M to \$120M assets total assets \$116.6M	
Warnings	short runway, thin data not computable: degenerate inputs, fortress balance sheet	
Inputs computable	6 of 14	
Graded from	filings received through Mar 6, 2026 217 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026	
Last close	\$1.49 2026-10-08; market equity \$79.7M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 6, 2026

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the "guardian of the genome," and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 72.7						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.7%)	(6.6%)	72.7	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 48.2						
Twelve-month failure probability		0.44%	0.07%	81.8	248	2026-06-30
Altman Z double-prime		(2.34)	(0.31)	46.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		10.09x	2.96x	16.2	839	2025-12-31
Growth and financing, sleeve percentile 62.1						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 0
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(24.5%)	2.1%	88.2	704	2025-12-31
Net share issuance, one year		2.7%	2.5%	36.0	634	2026-03-03

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.1 months
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(13.6%)	8.0%	36
Distance from 52-week high	(17.2%)	(31.4%)	69
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(92.4%)	(1.0%)	6
Book value to price	0.90	0.28	84
Sales to price	not computable	0.31	
Composite equity issuance, five years	17.7%	20.3%	48
Relative strength against the sector, log excess return	(0.36)	(0.14)	36

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$12.5M
Operating cash flow, four quarters	-\$71.3M
Months of runway	2.1
Days since last periodic filing	56 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	\$479,351

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$77.7M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$73.6M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
3	assets	us-gaap:Assets	\$116.6M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
4	assets	us-gaap:Assets	\$191.3M	2024-12-31	2026-03-06	10-K	0001193125-26-095014
5	current assets	us-gaap:AssetsCurrent	\$115.2M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
6	current liabilities	us-gaap:LiabilitiesCurrent	\$11.4M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$446.5M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
8	operating income	us-gaap:OperatingIncomeLoss	-\$86.2M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
9	book equity	us-gaap:StockholdersEquity	\$104.7M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
10	liabilities	us-gaap:Liabilities	\$11.8M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$29,000	2025-12-31	2026-03-06	10-K	0001193125-26-095014
12	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$51.3M	2024-12-31	2026-03-06	10-K	0001193125-26-095014
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$655,000	2024-12-31	2026-03-06	10-K	0001193125-26-095014
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$55.7M	2023-12-31	2026-03-06	10-K	0001193125-26-095014
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$962,000	2023-12-31	2026-03-06	10-K	0001193125-26-095014
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$63.8M	2022-12-31	2025-03-03	10-K	0000950170-25-030414
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.0M	2022-12-31	2025-03-03	10-K	0000950170-25-030414
18	depreciation amortization	us-gaap:Depreciation	\$133,000	2025-12-31	2026-03-06	10-K	0001193125-26-095014
19	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$19.9M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
20	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$2.2M	2025-12-31	2026-03-06	10-K	0001193125-26-095014
21	current assets	us-gaap:AssetsCurrent	\$175.7M	2024-12-31	2026-03-06	10-K	0001193125-26-095014
22	current liabilities	us-gaap:LiabilitiesCurrent	\$14.4M	2024-12-31	2026-03-06	10-K	0001193125-26-095014
23	assets	us-gaap:Assets	\$252.2M	2023-12-31	2025-03-03	10-K	0000950170-25-030414
24	assets	us-gaap:Assets	\$270.3M	2022-12-31	2024-02-29	10-K	0000950170-24-023062
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,329,392	2026-03-03	2026-03-06	10-K	0001193125-26-095014
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,933,604	2025-03-03	2025-03-03	10-K	0000950170-25-030414